STAAR Surgical Co. Form 8-K Summary
Business Context and Reporting Period
STAAR Surgical Company (STAA) filed this Current Report on March 3, 2026, to announce financial results for the quarter and fiscal year ended January 2, 2026. The company is incorporated in Delaware and trades on the NASDAQ. Leadership for this period includes Interim Co-CEOs and CFO Deborah Andrews.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release (Exhibit 99.1) and shareholder letter (Exhibit 99.2) referenced in the report but are not detailed in the 8-K body text itself.
Material Changes
No specific material changes or comparative financial data versus prior periods are disclosed in the text of this filing. Investors must refer to the attached exhibits for detailed performance comparisons.
Guidance, Outlook, and Management Commentary
Management scheduled a conference call and webcast for March 3, 2026, to discuss the results for the quarter and year ended January 2, 2026. The filing explicitly states that the information in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures for the quarter and year ended January 2, 2026.
- Examine Exhibit 99.2 (Shareholder Letter) for management's commentary on operational performance and strategic outlook.
- Verify the details of the conference call held on March 3, 2026, for any updated guidance or risk disclosures.
- Confirm the status of the interim executive leadership team and any potential succession plans.